Cisplatin is one of the most commonly used chemotherapy drugs, treating a wide range of
cancer types. Unfortunately, many cancers initially respond to platinum treatment but when …

The platinum derivative cis-diamminedichloroplatinum (II), best known as cisplatin, is
currently employed for the clinical management of patients affected by testicular, ovarian …

Objectives Methotrexate (MTX) is an important component of therapy for pediatric acute
lymphoblastic leukemia (ALL). Treatment with MTX often causes toxicity, which can …

The discovery of pharmacogenomic markers in colorectal cancer (CRC) could be setting-
specific. FOLFOX4 is employed in the adjuvant and metastatic setting in CRC. This …

Background Platinum‐based chemotherapy is the first‐line treatment of non‐small cell lung
cancer (NSCLC); it is therefore important to discover biomarkers that can be used to predict …

Several solute carriers and ATP-binding cassette transporters have been implicated in the
influx or efflux of platinum-based chemotherapeutic agents such as cisplatin, carboplatin …

Platinum-based chemotherapy (PBC) is a widely used treatment for various solid tumors,
including non-small cell lung cancer (NSCLC). However, its efficacy is often compromised …

Lung cancer is one of the leading causes of cancer-related death in the world. Platinum-
based chemotherapy is the first-line treatment for non-small-cell lung cancer (NSCLC) …

Background Platinum-based chemotherapy bring severe hematological toxicity that can lead
to dose reduction or discontinuation of therapy. Genetic variations have been reported to …

Platinum-induced myelosuppression severely impedes successful chemotherapy in non-
small-cell lung cancer (NSCLC) patients. Hence, it is clinically important to identify the …